RT Journal Article
SR Electronic
T1 The C-reactive Protein to Prealbumin Ratio Is an Independent Prognostic Factor for Patients With Gastric Cancer Who Receive Curative Surgery
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5181
OP 5187
DO 10.21873/anticanres.16719
VO 43
IS 11
A1 AOYAMA, TORU
A1 HASHIMOTO, ITARU
A1 MAEZAWA, YUKIO
A1 HARA, KENTARO
A1 KOMORI, KEISUKE
A1 OTANI, KAZUKI
A1 KAZAMA, KEISUKE
A1 SAWAZAKI, SHO
A1 NUMATA, MASAKATSU
A1 KAMIYA, NATSUMI
A1 KATO, AYA
A1 YAMADA, TAKANOBU
A1 NAGASAWA, SHINSUKE
A1 KAWAHARA, SHINNOSUKE
A1 CHO, HARUHIKO
A1 MORITA, JUNYA
A1 TANABE, MIE
A1 YUKAWA, NORIO
A1 SAITO, AYA
A1 RINO, YASUSHI
A1 OGATA, TAKASHI
A1 OSHIMA, TAKASHI
YR 2023
UL http://ar.iiarjournals.org/content/43/11/5181.abstract
AB Background/Aim: The C-reactive protein to prealbumin ratio (CPAR) has been proposed and introduced in gastrointestinal cancer management. This study aimed to evaluate the clinical impact of the CPAR in patients with gastric cancer (GC) who received curative treatment. Patients and Methods: This study included 447 patients who underwent curative treatment for GC between 2013 and 2017. The prognosis and clinicopathological parameters were compared between patients with high and low CPARs. Results: Overall survival (OS) stratified by each clinical factor was compared using the log-rank test, and a significant difference was observed using a pretreatment CPAR of 5.0. Significant differences were observed in the 3- and 5-year OS rates of the CPAR-low (CPAR <5.0) and CPAR-high (CPAR ≥5.0) groups. The 3- and 5-year OS rates were 92.6% and 87.8%, respectively, in the CPAR-low group and 88.0% and 75.4% in the CPAR-high group. The CPAR was determined to be a significant prognostic factor for OS in a multivariate analysis (p=0.032). Similar results were observed for recurrence-free survival. Conclusion: The CAPR is a prognostic factor for GC patients. Therefore, the CAPR may be a promising nutritional biomarker of inflammation that can be applied in the management of GC patients.